|  |
| --- |
| Supplementary Material. Main characteristics of the rapid HTA reports  |
| **Report Number** | **Technology Category** | **Technology** | **Population/s** | **Level of Evidence** | **Net Benefit** | **Cost-Effectiveness and Budget Impact** | **Recommendation (color of the traffic light)a** |
| 1 | High-Cost Drugs | Trastuzumab | in HER2+ metastatic gastric or gastroesophageal junction adenocarcinoma  | High | Major | Uncertain | Yellow/Green |
| 2 | Procedures and Devices | CPAP | vs common OSAHS therapies | Moderate | Minor | Uncertain | Yellow/Red |
| 3 | Procedures and Devices | Thyrogen® | vs. Interruption of thyroid replacement therapy in post-thyrodectomized patients with differentiated thyroid carcinoma | High | Minor | Uncertain | Yellow/Red |
| 4 | Procedures and Devices | Endovascular Repair with endoprosthesis  |  versus abdominal or thoracic aortic aneurysm repair open surgery | High | Considerable | Uncertain | Yellow/Green |
| 5 | High-Cost Drugs | Intensity-modulated radiotherapy | in head and neck cancer | Moderate | Considerable | Uncertain | Yellow |
| 5 | High-Cost Drugs | Intensity-modulated radiotherapy | in prostate cancer | High | Considerable | Uncertain | Yellow/Green |
| 6 | High-Cost Drugs | Intensity-modulated radiotherapy |  in breast or lung cancer  | Low | Marginal/ Null/ Uncertain | Uncertain | Red |
| 6 | High-Cost Drugs | Intensity-modulated radiotherapy | in anorectal cancer. | Very Low | Marginal/ Null/ Uncertain | Uncertain | Red |
| 7 | High-Cost Drugs | Dabrafenib plus trametinib or vemurafenib  | versus placebo as an adjuvant therapy | Moderate | Minor | Unreasonable | Red |
| 7 | High-Cost Drugs | Combined use of BRAF and MEK Inhibitors | in patients with advanced melanoma  | High | Major | Unreasonable | Yellow |
| 8 | High-Cost Drugs | Posaconazole | vs. fluconazole in oral candidiasis in HIV neutropenic patients or as a prophylactic treatment in patients diagnosed with graft vs. host disease receiving hematopoietic cells  | High | Minor | Uncertain | Yellow/Red |
| 8 | High-Cost Drugs | Posaconazole | vs. fluconazole and itraconazole for prophylactic treatment in neutropenic patients following chemotherapy for acute myeloid leukemia or myelodysplastic syndrome | High | Major | Uncertain | Yellow/Green |
| 9 | High-Cost Drugs | Pertuzumab plus trastuzumab  | as a neoadjuvant in patients with HER2+ breast cancer | Low | Minor | Uncertain | Red |
| 9 | High-Cost Drugs | Pertuzumab plus trastuzumab  | as an adjuvant in patients with HER2+ breast cancer | Moderate | Minor | Uncertain | Yellow/Red |
| 9 | High-Cost Drugs | Pertuzumab plus trastuzumab  | as a treatment with advanced HER2+ breast cancer | Moderate | Major | Uncertain | Yellow/Green |
| 10 | High-Cost Drugs | Pegvisomant  | as an adjuvant treatment in patients con acromegaly | Moderate | Minor | Unreasonable | Red |
| 10 | High-Cost Drugs | Pegvisomant  | in acromegaly with no response to surgical and/or radiotherapeutic treatment and/or medical treatment with somatostatin analogs | Moderate | Considerable | Uncertain | Yellow |
| 11 | Procedures and Devices | Extracorporeal membrane oxygenation |  vs. Protective invasive mechanical ventilation in patients with severe respiratory distress syndrome | Moderate | Marginal/ Null/ Uncertain | Uncertain | Red |
| 11 | Procedures and Devices | Extracorporeal membrane oxygenation | vs. Counterpulsation balloon in patients with severe heart failure | Low | Minor | Uncertain | Red |
| 12 | Procedures and Devices | Oncotype DX® | versus the usual criteria for treatment decision | Moderate | Minor | Unreasonable | Red |
| 13 | High-Cost Drugs | New oral anticoagulants | vs. Low-molecular weight heparin for prevention of thromboembolism in patients requiring major orthopedic surgery  | High | Considerable | Uncertain | Yellow/Green |
| 14 | High-Cost Drugs | New oral anticoagulants |  for non-valvular atrial fibrillation patients as a first line of treatment | Low | Minor | Uncertain | Red |
| 14 | High-Cost Drugs | New oral anticoagulants | for non-valvular atrial fibrillation patients as a second line of treatment | High | Minor | Uncertain | Yellow/Red |
| 15 | Procedures and Devices |  MammaPrint® genomic expression test | in patients with early-stage breast cancer and high risk of recurrence according to clinical/pathological criteria, hormone receptors positive, and HER2 negative. | Low | Minor | Uncertain | Red |
| 16 | High-Cost Drugs | Immunocyanin |  vs. BCG vaccine for prevention of non-infiltrating bladder cancer relapse | Very Low | Marginal/ Null/ Uncertain | Unreasonable | Red |
| 16 | High-Cost Drugs | Immunocyanin | mitomycin C for prevention of non-infiltrating bladder cancer relapse | Low | Marginal/ Null/ Uncertain | Unreasonable | Red |
| 17 | Procedures and Devices | Ventricular assist devices | for patients with end-stage heart failure | Moderate | Considerable | Unreasonable | Yellow/Red |
| 18 | High-Cost Drugs | Plasma-derived C1 inhibitor |  in the treatment of severe abdominal, facial, or laringeal acute episode of hereditary angioedema | High | Considerable | Uncertain | Yellow/Green |
| 19 | Procedures and Devices | Deep brain stimulation | in advanced Parkinson's disease  | High | Considerable | Uncertain | Yellow/Green |
| 20 | High-Cost Drugs | Enzalutamida  | in metastatic prostate cancer | High | Major | Unreasonable | Yellow |
| 21 | Procedures and Devices | Aortic valve replacement | in patients with severe symptomatic aortic stenosis with medium to high risk for open-heart aortic valve replacement surgery. | High | Marginal/ Null/ Uncertain | Uncertain | Red |
| 21 | Procedures and Devices | Aortic valve replacement | in patients with severe symptomatic aortic stenosis with medium to high risk for open-heart aortic valve replacement surgery. | High | Major | Uncertain | Yellow/Green |
| 22 | High-Cost Drugs | Eculizumab | vs. usual treatments in patients with atypical hemolytic uremic syndrome | Low | Considerable | Uncertain | Yellow/Red |
| 22 | High-Cost Drugs | Eculizumab | vs. placebo in patients with paroxysmal nocturnal hemoglobinuria | Moderate | Considerable | Uncertain | Yellow |
| 23 | Procedures and Devices | Cryoablation | vs. radio-frequency ablation in the treatment of symptomatic or persistent paroxysmal atrial fibrillation | Moderate | Considerable | Reasonable | Green |
| 24 | Procedures and Devices | Fetal surgery |  for intrathoracic lesions, fetal-pleural shunt, congenital diaphragmatic hernia, lower urinary tract obstruction, intra-uterine intravascular transfusion, reverse arterial perfusion syndrome, sacrococcygeal teratoma  | Moderate | Minor | Uncertain | Yellow/Red |
| 24 | Procedures and Devices | Fetal surgery | for myelomeningocele and feto-fetal transfusion syndrome | High | Considerable | Uncertain | Yellow/Green |
| 25 | Procedures and Devices | Insulin continuous subcutaneous infusion systems | vs. multiple insulin injections in diabetic patients as a therapeutic alternative | Moderate | Minor | Unreasonable | Red |
| 25 | Procedures and Devices | Insulin continuous subcutaneous infusion systems | vs. multiple insulin injections in Type I diabetic patients with poor glycemic control | Moderate | Considerable | Uncertain | Yellow |
| 26 | High-Cost Drugs | Recombinant human alpha-glucosidase | in Pompe disease | Low | Major | Uncertain | Yellow |
| 27 | High-Cost Drugs | Hyaluronic acid | vs. other second line alternatives in bladder pain syndrom/interstitial cystitis  | Moderate | Considerable | Uncertain | Yellow |
| 28 | High-Cost Drugs | Abiraterone | in metastatic prostate cancer | High | Major | Unreasonable | Yellow |
| 29 | High-Cost Drugs | Bexarotene as a mono- or combination therapy | vs. other therapeutic alternatives in cutaneous lymphoma | Moderate | Minor | Unreasonable | Red |
| 30 | Procedures and Devices | Single or dual chamber implantable cardioverter defibrillator | in secondary prevention of sudden death | High | Considerable | Uncertain | Yellow/Green |
| 30 | Procedures and Devices | Single or dual chamber implantable cardioverter defibrillator | in primary prevention of sudden death | High | Major | Reasonable | Green |
| 31 | High-Cost Drugs | Fingolimod | in relapsing-remitting Multiple Sclerosis | High | Considerable | Uncertain | Yellow/Green |
| 32 | High-Cost Drugs | Teriflunomide | in Multiple Sclerosis | Moderate | Minor | Uncertain | Yellow/Red |
| 33 | High-Cost Drugs | Trastuzumab emtansine with or without pertuzumab |  versus chemotherapy\* in HER2+ breast cancer as a first line in advanced stage disease, or as a neoadjuvant in stages II and III. | Moderate | Marginal/ Null/ Uncertain | Uncertain | Red |
| 33 | High-Cost Drugs | Trastuzumab emtansine | versus chemotherapy in HER2+ breast cancer as a second line of treatment  | High | Major | Unreasonable | Yellow |
| 34 | Procedures and Devices | Lynch symdrome genetic testing |  versus no testing in colorectal cancer patients | Moderate | Considerable | Uncertain | Yellow |
| 35 | High-Cost Drugs | Enzyme replacement therapy with agalsidase alpha or beta |  vs. placebo inFabry's disease | Moderate | Minor | Uncertain | Yellow/Red |
| 36 | High-Cost Drugs | Bortezomib |  in relapsing or refractory mantle cell lymphoma | Low | Considerable | Uncertain | Yellow/Red |
| 36 | High-Cost Drugs | Bortezomib schemes |  versus other schemes as a first line of treatment of mantle cell lymphoma  | High | Considerable | Uncertain | Yellow/Green |
| 37 | High-Cost Drugs | Antiangiogenic therapy |  vs. laser therapy in patients with diabetic retinopathy | High | Minor | Uncertain | Yellow/Red |
| 38 | High-Cost Drugs | Romiplostin or eltrombopag | vs. placebo in pediatric patients with chronic or refractory ITP | Moderate | Considerable | Unreasonable | Yellow/Red |
| 38 | High-Cost Drugs | Romiplostin or eltrombopag |  vs. placebo in adult patients with chronic or refractory ITP | Moderate | Major | Unreasonable | Yellow |
| 39 | High-Cost Drugs | Antiangiogenic drugs |  vs. the usual treatment for age-related macular degeneration  | Moderate | Considerable | Uncertain | Yellow |
| 40 | High-Cost Drugs | Antiangiogenic drugs |  vs. Corticoid or laser therapy in patients with retinal vein occlusion | Moderate | Considerable | Uncertain | Yellow |
| 41 | Procedures and Devices | Spinal cord stimulation |  for chronic neuropathic pain management versus a conventional medical treatment | Moderate | Considerable | Uncertain | Yellow |
| 42 | Procedures and Devices | Occlusive devices |  for interatrial communication and arterial and ductus venosus  | Moderate | Considerable | Uncertain | Yellow |
| 43 | Procedures and Devices | Percutaneous closure of patent foramen ovale | for the prevention of cerebrovascular accident vs medical treatment | High | Considerable | Uncertain | Yellow/Green |
| 44 | High-Cost Drugs | Ruxolitinib |  vs. placebo or other therapies in patients with myelofibrosis | Moderate | Minor | Uncertain | Yellow/Red |
| 45 | Procedures and Devices | Artificial urinary sphincter | in patients with severe urinary incontinence and failure of prior treatments  | Moderate | Minor | Uncertain | Yellow/Red |
| 46 | High-Cost Drugs | Epoprostenol | vs. placebo in patients with Pulmonary Arterial Hypertension group I  | Moderate | Considerable | Uncertain | Yellow |
| 46 | High-Cost Drugs | Iloprost o Treprostinil  | vs. placebo in patients with Pulmonary Arterial Hypertension group I | Moderate | Minor | Uncertain | Yellow/Red |
| 46 | High-Cost Drugs | Epoprostenol  | vs. iloprost or treprostinil in patients with Pulmonary Arterial Hypertension group I | Low | Minor | Uncertain | Red |
| 47 | High-Cost Drugs | Velaglucerase/ Imiglucerase  | in Gaucher disease type I and type II (shows clinically important non-neurological signs of the disease) | Low | Considerable | Uncertain | Yellow/Red |
| 48 | Procedures and Devices | Positron Emission tomography (PET) |  for non-oncologic diseases (cardiac device infections, dementias, refractory epilepsy, myocardial viability) | Low | Minor | Unreasonable | Red |
| 49 | Procedures and Devices | Positron Emission tomography (PET) | Oncologic diseases  |   |   |   |   |
| 50 | Procedures and Devices | Nuchal translucency screening | Pre natal screening |   |   |   |   |
| 51 | Outpatient essential medicine list  | Varenicline | smoking cessation aid | High | Considerable | Uncertain | Yellow/Green |
| 52 | High-Cost Drugs | Labetalol | in pregnant women with mild hypertension | Moderate | Minor | Unreasonable | Red |
| 52 | High-Cost Drugs | Labetalol | in pregnant women with severe hypertension | Moderate | Considerable | Reasonable | Green |
| 53 | High-Cost Drugs | Oseltamivir | in influenza-like illness | Moderate | Minor | Uncertain |   |
| 54 | Procedures and Devices | HPV Test | for cervical-uterine cancer screening | High | Considerable | Uncertain | Yellow/Green |
| 55 | Outpatient essential medicine list  | Benznidazole | in the chronic phase of Chagas Disease | Moderate | Marginal/ Null/ Uncertain | Uncertain | Red |
| 55 | Outpatient essential medicine list  | Benznidazole | in vertical transmission in women of childbearing age with chronic illness | Low | Considerable | Uncertain | Yellow/Red |
| 55 | Outpatient essential medicine list  | Benznidazole | in the acute phase of Chagas Disease | Low | Considerable | Reasonable | Yellow/Green |
| 56 | High-Cost Drugs | Erlotinib | in pancreatic cancer | Moderate | Marginal/ Null/ Uncertain | Unreasonable | Red |
| 57 | Procedures and Devices | Oxygen therapy | in COPD | Moderate | Major | Uncertain | Yellow/Green |
| 58 | Outpatient essential medicine list  | Bupropion | smoking cessation aid | High | Considerable | Uncertain | Yellow/Green |
| 59 | High-Cost Drugs | Biological agents | in juvenile idiopatic arthritis  | Moderate | Major | Uncertain | Yellow/Green |
| 60 | High-Cost Drugs | Bevacizumab | in advanced breast cancer | High | Marginal/ Null/ Uncertain | Unreasonable | Red |
| 61 | Procedures and Devices | Etonogestrel-releasing subcutaneous implant | in contraception | High | Considerable | Reasonable | Green |
| 62 | Procedures and Devices | Levonorgestrel-releasing subcutaneous implant | vs. copper intrauterine device | High | Minor | Unreasonable | Red |
| 63 | High-Cost Drugs | Bevacizumab | in advanced lung cancer | High | Minor | Unreasonable | Red |
| 64 | High-Cost Drugs | Biological agents and Tofacitinib | in rheumatoid arthritis | High | Major | Uncertain | Yellow/Green |
| 65 | High-Cost Drugs | Biological agents | in adults with spondyloarthritis | Moderate | Considerable | Uncertain | Yellow |
| 66 | High-Cost Drugs | Sofosbuvir | in chronic hepatitis C virus type 1, 2, 3, or 4 hepatitis with one or more high risk conditions | High | Considerable | Uncertain | Yellow/Green |
| 67 | High-Cost Drugs | Ombitasvir/paritaprevir/ritonavir | in chronic hepatitis C virus genotype 1 or 4 hepatitis | High | Considerable | Uncertain | Yellow/Green |
| 68 | Outpatient essential medicine list  | Glucagon-like peptide-1 recdeptor agonists  | in patients with diabetes mellitus Type 1 or Type 2 | Moderate | Marginal/ Null/ Uncertain | Uncertain | Red |
| 68 | Outpatient essential medicine list  | Lliraglutide addition | in poorly controlled diabetes type 2 patients with cardiovascular or cerebrovascular disease | Moderate | Major | Uncertain | Yellow/Green |
| 69 | Outpatient essential medicine list  | Dipeptidyl peptidase-4 inhibitors | in diabetes mellitus type 2 | High | Marginal/ Null/ Uncertain | Uncertain | Red |
| 70 | Procedures and Devices | BRCA gene mutation testing | in women with breast and/or ovarian cancer with high pretest probability | Moderate | Considerable | Uncertain | Yellow |
| 71 | Outpatient essential medicine list  | Insulin degludec | vs. glargine i in diabetes type 1 or type 2 patients | High | Minor | Uncertain | Yellow/Red |
| 72 | High-Cost Drugs | Intravitreal bevacizumab | vs. laser in retinopathy of prematurity | Low | Marginal/ Null/ Uncertain | Uncertain | Red |
| 73 | Outpatient essential medicine list  | Tiazolidinediones with metformin | in type 2 diabetes with poor glycemic control | High | Marginal/ Null/ Uncertain | Reasonable | Red |
| 74 | Procedures and Devices | Bilateral cochlear implants | compared to unilateral implants | Moderate | Minor | Uncertain | Yellow/Red |
| 75 | -  | Assisted reproduction treatments |   |   |   |   |   |

CPAP: continuous positive airway pressure; ECMO: Extracorporeal Membrane Oxygenation; PET: Positron Emission Tomography; COPD: Chronic Obstructive Pulmonary Disease

Note: Some quick reports resulted in the evaluation of multiple technologies that included drugs and / or procedures, such as report number 75, Assisted reproduction treatments . These reports do not have a resulting color on the traffic light scale.

(a) Traffic light scale recommendation: Green: The available information is favorable to the incorporation of this technology; Yellow/Green: The available information does not allow a definitive recommendation although there are elements that would favor their incorporation; Yellow: The available information does not allow a definitive recommendation for their incorporation; Yellow/Red: The information available does not allow for a definitive recommendation. Certain features suggest against their incorporation; Red: The available information is contraty to the incorporation of this technology